Prices are updated after-hours

Manufacturing 2022 - 08 - 04

Crona Corp.

CCCP | $0.16 0% 5K

(0.0% 1d) (0.0% 1m) (-70.9% 1y) (0.0% 2d) (0.0% 3d) (33.1% 7d) (25.0% volume)
Earnings Calendar:
Market Cap: $ 1,854,000

Sec Filling | Patents | 1 employees

add to watch list Paper trade email alert is off

Longwen Group Corp.

LWLW | $0.11 245.46% 350

Manufacturing

(0.0% 1d) (0.0% 1m) (-59.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-48.44% volume)
Earnings Calendar:
Market Cap: $ 8,780,760

Sec Filling | Patents | n/a employees

(US)

add to watch list Paper trade email alert is off

IDEX Biometrics ASA - ADR

IDBA | $4.88 1.67% 0.0% 9

Manufacturing

(0.0% 1d) (0.0% 1m) (-22.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (578.89% volume)
Earnings Calendar:
Market Cap: $ 85,629,931
https://www.idexbiometrics.com/
Sec Filling | Patents | 77 employees

(NO) crossword cybersecurity is a technology commercialisation company focusing exclusively on the cyber security sector. we work with research intensive european university partners to identify promising cyber security intellectual property ("ip") from research that our industry partners tell us meet emerging real-world challenges. our specialist cyber security software engineering team work with our university partners to develop the research concept into a fully fledged commercial product that we bring to market. our first product, rizikon (www.rizikon.io) is a cyber risk analysis and investment prioritisation tool that can help you understand where your biggest vulnerabilities are and how to invest in protecting against them. crossword cybersecurity plc was founded in 2014.

add to watch list Paper trade email alert is off

Immune Therapeutics, Inc.

IMUN | $0.093 214.52% 1.8K

Manufacturing

(0.0% 1d) (0.0% 1m) (-84.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (52.37% volume)
Earnings Calendar:
Market Cap: $ 7,780,180
https://www.immunetherapeutics.com/
Sec Filling | Patents | 2 employees

(US) immune therapeutics is a specialty pharmaceutical company involved in the manufacturing, distribution and marketing of our novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system. company’s technology platform is built on two different immunotherapies, low dose naltrexone (ldn) and methionine-enkephalin (menk). both therapies have been decades in the making at institutions such as the pennsylvania state university medical school at hershey, university of chicago, state university of new york, and multiple sclerosis center at ucsf.

add to watch list Paper trade email alert is off

Williams Industrial Services Group Inc

WLMS | $0.3572 -3.17% 0.0% 0

Manufacturing

(0.0% 1d) (-3.2% 1m) (-62.0% 1y) (-3.2% 2d) (-3.4% 3d) (0.0% 7d) (637.87% volume)
Earnings Calendar:
Market Cap: $ 9,719,552
https://www.wisgrp.com
Sec Filling | Patents | 460 employees

(US) Williams Industrial Services Group has been safely helping plant owners and operators enhance asset value for more than 50 years. The Company provides a broad range of construction, maintenance and modification, and support services to customers in energy and industrial end markets. Williams' mission is to be the preferred provider of construction, maintenance, and specialty services through commitment to superior safety performance, focus on innovation, and dedication to delivering unsurpassed value to its customers.

energy construction

add to watch list Paper trade email alert is off

IM Cannabis Corp

IMCC | $0.611 -15.93% -18.95% 600K

Manufacturing

(0.0% 1d) (128.8% 1m) (44.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-62.84% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 8,181,016
https://imcannabis.com
Sec Filling | Patents | 2020 employees

IMC is an MCO in the medical cannabis sector headquartered in Israel and with operations In Israel and Germany. Over the past decade, the Company believes that the IMC brand has become synonymous with quality and consistency in the Israeli medical cannabis market. The Company has also expanded its business to offer intellectual property-related services to the medical cannabis industry. In Europe, IMC operates through Adjupharm GmbH ("Adjupharm"), a German-based subsidiary and EU-GMP certified medical cannabis distributor. IMC's European presence is augmented by strategic alliances with various pan-European EU-GMP cultivators and distributors to capitalize on the increased demand for medical cannabis products in Europe and bring the IMC brand and its product portfolio to European patients.

israel brands cannabis

add to watch list Paper trade email alert is off

Diversey Holdings Ltd

DSEY | $8.39 0.12% 1.7M

Manufacturing

(0.0% 1d) (0.0% 1m) (3.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (289.64% volume)
Earnings Calendar: 2023-08-03
Market Cap: $ 2,723,219,647
https://www.diversey.com
Sec Filling | Patents | 8500 employees

(US) Diversey’s mission is to protect and care for people through leading hygiene, infection prevention, and cleaning solutions. The company develops and delivers innovative products, services, and technologies that save lives and protect the environment. Over the course of 95 years, the Diversey brand has become synonymous with product quality, service, and innovation.

brands injection

add to watch list Paper trade email alert is off

NUTRA PHARMA CORP

NPHC | $0.0001 2900.0% 3

Manufacturing

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-99.81% volume)
Earnings Calendar:
Market Cap: $ 706,474

Sec Filling | Patents | 4 employees

nutra pharma corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. the company carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. currently, nutra pharma offers several drug products for sale for the treatment of pain: nyloxin, the first over-the-counter (otc) pain reliever clinically proven to treat moderate to severe (stage 2) chronic pain, and nyloxin extra strength, the only non-narcotic and non-addictive treatment for severe (stage 3) pain. see: www.nyloxin.com nutra pharma also offers pet pain-away: a product aimed at treating moderate to severe chronic pain in companion animals. pet pain-away is specifically indicated to treat pain from hip dysplasia, arthrit

education

add to watch list Paper trade email alert is off

BRAIN SCIENTIFIC INC.

BRSF | $0.75 70.91% 800

Manufacturing

(0.0% 1d) (0.0% 1m) (-30.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (433.33% volume)
Earnings Calendar:
Market Cap: $ 931,985
https://www.brainscientific.com/
Sec Filling | Patents | 7 employees

(US) brain scientific inc. operates as a neurodiagnostic and predictive technology platform company in the united states. the company provides a platform for data acquisition and analysis of electroencephalography (eeg) data that combines medical device technologies with cloud-based telehealth services. it offers neurocap, a disposable and soft layered cap with an integrated electrode circuit that is designed to address existing problems of conventional eeg systems; and neuroeeg, a cloud-enabled data acquisition platform for electroencephalogram activity, as well as neuronet cloud, a database where brain data can be stored and analyzed. the company also sells its products through online store, brainscientific.myshopify.com. brain scientific inc. was founded in 2015 and is headquartered in bohemia, new york.

add to watch list Paper trade email alert is off

PROCEPT BioRobotics Corp

PRCT A | $52.57 -2.2% 210K

Manufacturing

(0.0% 1d) (14.3% 1m) (50.5% 1y) (0.0% 2d) (6.2% 3d) (7.1% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 2,702,106,201
https://www.procept-biorobotics.com
Sec Filling | Patents | 2021 employees

PROCEPT is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

add to watch list Paper trade email alert is off

Purple Biotech Ltd - ADR

PPBT | $0.545 11.22% 170K

Manufacturing

(0.0% 1d) (-21.7% 1m) (-75.3% 1y) (0.0% 2d) (8.9% 3d) (6.5% 7d) (-21.7% volume)
Earnings Calendar:
Market Cap: $ 14,164,830
http://kitovpharma.com
Sec Filling | Patents | 13 employees

(IL) kitov pharmaceuticals ltd. is a financial services company located in israel.

add to watch list Paper trade email alert is off

Ecovyst Inc

ECVT | $9.89 -2.08% 250K

Manufacturing

(0.0% 1d) (-4.0% 1m) (-8.3% 1y) (0.0% 2d) (1.7% 3d) (1.5% 7d) (-29.96% volume)
Earnings Calendar:
Market Cap: $ 1,157,130,000
https://ecovyst.com
Sec Filling | Patents | 2274 employees

PQ Group Holdings Inc. and subsidiaries is a leading integrated and innovative global provider of specialty catalysts, materials, chemicals and services. We support customers globally through our strategically located network of manufacturing facilities. PQ Group has four uniquely positioned specialty businesses: Refining Services provides sulfuric acid recycling to the North American refining industry; Catalysts serves the packaging and engineering plastics and the global refining, petrochemical and emissions control industries; Performance Materials produces transportation reflective safety markings for roads and airports; and Performance Chemicals supplies diverse product end uses, including personal and industrial cleaning products, fuel-efficient tires, surface coatings, and food and beverage products. PQ Group serves over 4,000 customers globally across many end uses and operate over 70 manufacturing facilities which are strategically located across six continents.

food

add to watch list Paper trade email alert is off

MillerKnoll Inc

MLKN | $25.25 -3.48% 110K

Manufacturing

(0.0% 1d) (-12.4% 1m) (55.6% 1y) (0.0% 2d) (2.4% 3d) (4.1% 7d) (50.14% volume)
Earnings Calendar: 2024-03-27
Market Cap: $ 1,808,879,624
https://www.hermanmiller.com
Sec Filling | Patents | 7600 employees

(US) Herman Miller is a globally recognized leader in design. Since its inception in 1905, the company's innovative, problem-solving designs and furnishings have inspired the best in people wherever they live, work, learn, heal, and play. In 2018, Herman Miller created Herman Miller Group, a purposefully selected, complementary family of brands that includes Colebrook Bosson Saunders, Design Within Reach, Geiger, HAY, Maars Living Walls, Maharam, naughtone, and Nemschoff. Guided by a shared purpose-design for the good of humankind-Herman Miller Group shapes places that matter for customers while contributing to a more equitable and sustainable future for all.

brands

add to watch list Paper trade email alert is off

374Water Inc.

SCWO | $1.32 -1.49% 17K

Manufacturing

(0.0% 1d) (12.6% 1m) (-47.0% 1y) (0.0% 2d) (7.2% 3d) (6.3% 7d) (123.02% volume)
Earnings Calendar:
Market Cap: $ 175,120,581

Sec Filling | Patents | 3 employees

globally, 4.5 billion people lack access to safely managed sanitation, with enormous costs to society. energy efficient sanitation with water reuse is needed to address future water scarcity. 374water offer prefabricated, compact and superior treatment systems utilizing supercritical water oxidation technology that converts organic waste to clean water in seconds, eliminating all pathogens and micropollutants, while recovering energy and nutrients.

pathogens energy

add to watch list Paper trade email alert is off

Sylvamo Corp

SLVM 4 | $62.225 0.14% 42K

Manufacturing

(0.0% 1d) (2.7% 1m) (37.0% 1y) (0.0% 2d) (2.5% 3d) (6.3% 7d) (-22.62% volume)
Earnings Calendar:
Market Cap: $ 2,579,951,607
https://www.sylvamo.com
Sec Filling | Patents | 2021 employees

Sylvamo is the world’s paper company with mills in Europe, Latin America and North America. Our vision is to be the employer, supplier and investment of choice. We transform renewable resources into papers that people depend on for education, communication and entertainment. Headquartered in Memphis, Tennessee, we employ more than 7,000 colleagues. Net sales for the last 12 months ending June 30, 2021, were $3.2 billion.

communication renewable education

add to watch list Paper trade email alert is off

Avalo Therapeutics Inc

AVTX | $13.46 3.54% 21K

Manufacturing

(0.0% 1d) (168.6% 1m) (337.7% 1y) (0.0% 2d) (6.5% 3d) (8.2% 7d) (-11.97% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 13,919,390
https://www.cerecor.com
Sec Filling | Patents | 31 employees

(United States) Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.

monoclonal antibodies antibody covid respiratory treatment

add to watch list Paper trade email alert is off

AMERICAN REBEL HOLDINGS INC

AREB | News | $0.356 -0.34% 170K

Manufacturing

(0.0% 1d) (19.3% 1m) (-89.4% 1y) (0.0% 2d) (2.9% 3d) (16.1% 7d) (468.22% volume)
Earnings Calendar:
Market Cap: $ 2,117,361

Sec Filling | Patents | 2 employees

(US)

add to watch list Paper trade email alert is off

Edgewise Therapeutics Inc

EWTX | $15.905 1.63% 210K

Manufacturing

(0.0% 1d) (-2.2% 1m) (101.2% 1y) (0.0% 2d) (3.8% 3d) (2.8% 7d) (47.23% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 1,480,924,459
https://edgewisetx.com
Sec Filling | Patents | n/a employees

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.

drug discovery treatment

add to watch list Paper trade email alert is off

First Wave BioPharma, Inc.

FWBI | $3.12 6.1K

Manufacturing

(0.0% 1d) (-24.3% 1m) (12.2% 1y) (0.0% 2d) (7.2% 3d) (9.9% 7d) (-100.0% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 6,318,621
https://www.azurrx.com
Sec Filling | Patents | 12 employees

(US) AzurRx BioPharma, Inc. is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, FW-420, for grade 1 Immune Checkpoint Inhibitor Colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California.

covid disease treatment phase 2 biopharma diarrhea fibrosis clinical trials test gastrointestinal trials trial pancreatic injection

add to watch list Paper trade email alert is off

Figs Inc - Class A

FIGS | $4.84 1.04% 1.2M

Manufacturing

(0.0% 1d) (0.8% 1m) (-25.0% 1y) (0.0% 2d) (0.6% 3d) (0.0% 7d) (-35.47% volume)
Earnings Calendar:
Market Cap: $ 782,278,746
https://www.wearfigs.com
Sec Filling | Patents | 202 employees

FIGS is a founder-led, direct-to-consumer healthcare apparel and lifestyle brand that seeks to celebrate, empower and serve current and future generations of healthcare professionals. The company creates technically advanced apparel and products for healthcare professionals that feature an unmatched combination of comfort, durability, function and style. FIGS markets and sells its products directly through its digital platform to provide a seamless experience for healthcare professionals.

brands

add to watch list Paper trade email alert is off